Dulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event risk
1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in…
FDA approves pill which can prevent heart attack, stroke by reducing inflammation: How it works
The U.S. Food and Drug Administration (FDA) has made a major move in heart health care by approving…